NCT02642250 (HA) is a Phase 2/Phase 3 clinical trial of Metronidazole in Chronic Diarrhea, sponsored by Shifa Ul Mulk Memorial Hospital.

Who is sponsoring NCT02642250?

NCT02642250 is sponsored by Shifa Ul Mulk Memorial Hospital.

What drugs are being tested in NCT02642250?

Interventions in NCT02642250: Metronidazole, Entoban.

What condition does NCT02642250 study?

NCT02642250 studies Chronic Diarrhea.

Is NCT02642250 still recruiting?

NCT02642250 is currently completed. Last updated 30 December 2015.

Last reviewed 2015-12-30 · How we verify

NCT02642250: HA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemical, Biological and Comparative Clinical Evaluation of Entoban to Determine Safety and Efficacy for the Treatment of Chronic Diarrhea

Completed Phase 2/Phase 3 Last updated 30 December 2015

What this trial tests

Phase 2/Phase 3 trial testing Metronidazole in Chronic Diarrhea in 70 participants. Completed in 1 December 2015.

Timeline

1 January 2015

Primary endpoint
1 December 2015

1 December 2015

Quick facts

Lead sponsor	Shifa Ul Mulk Memorial Hospital
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	1 January 2015
Primary completion	1 December 2015
Estimated completion	1 December 2015
Sites	1 location across Pakistan

Drugs / interventions tested

Metronidazole (METRONIDAZOLE) — full drug profile →
Entoban — full drug profile →

Conditions studied

Chronic Diarrhea — all drugs for Chronic Diarrhea →

Sponsor

Shifa Ul Mulk Memorial Hospital

Who can join

Adults 18 to 60, any sex, with Chronic Diarrhea. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Stool D/R
Time frame: 5 days
The primary efficacy criterion will be the frequency and consistency of diarrhea in hours, from the first treatment dose to recovery. It will be evaluated through stool D/R. Stool D/R described the consistency, frequency and other important features of stool. Semisolid stool consistency with 1-2/day will be considered significant.

Sponsor's own description

Revival of significance and the emergent market of herbal medicinal products necessitate strong commitment by the stakeholders to safeguard the end users. The variability in the concentrations of constituents of plant material, coupled with the variety of extraction techniques and processing steps used by different manufacturers, results in distinct inconsistency in the quality of herbal products. The present study will be directed to a polyherbal formulation Entoban which integrates an outstanding blend of herbs that have been used for decades to eradicate microorganisms and worms from gastrointestinal tract. It is the combination of Holarrhena antidysenterica, Berberis aristata, Symplocos racemosa, Querecus infectoria and Helicteres isora. The current study would target the chemical assessment, pharmacological and comparative clinical evaluation of Entoban to assure its safety and efficacy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and safety of Entoban for the treatment of chronic diarrhea.
Shakeel S, Usmanghani K, Asif HM. · · 2016 · PMID 28167477

Verify or expand the search:

Other trials of Metronidazole

Trials testing the same drug.

NCT07180615 — Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon Surgery · Phase 4 · not yet recruiting
NCT07492134 — APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) · Phase 2 · not yet recruiting
NCT06627270 — Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer · Phase 2 · recruiting
NCT06616597 — Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Meta · Phase 2 · recruiting
NCT06798415 — Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis · Phase 2 · recruiting

Other recruiting trials for Chronic Diarrhea

Currently open trials in the same condition.

NCT06960369 — Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, · Phase 1 · recruiting
NCT06530836 — Chronic Diarrhea Owing to Underlying Microscopic Colitis · active not recruiting

Other Shifa Ul Mulk Memorial Hospital trials

Trials by the same sponsor.

NCT05572268 — EFFICACY OF ANSA (Experimental Drug) & CRAN MAX (Control Drug) SACHET · Phase 3 · unknown
NCT05563064 — Effect of Herbal Formulation on Thrombocytes Count · Phase 3 · unknown
NCT03506919 — Comparative Clinical Efficacy and Safety of Coded Polyherbal Medicine for the Management of Arthritis · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02642250 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shifa Ul Mulk Memorial Hospital
Last refreshed: 30 December 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02642250.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing